ACE inhibitors and angiotensin II receptor blockers. Treatment of pediatric arterial hypertension;Arterielle Hypertonie im Kindes- und Jugendalter. Behandlung mit ACE-Hemmern und Angiotensin-II-Rezeptorantagonisten

Padiatrische Praxis

Volumn 70, Issue 1, 2007, Pages 29-40

  Cortina, Gerard ^a,b   Wiesmayr, S ^a   Jungraithmayr, T C ^a   Zimmerhackl, L B ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

ACE inhibitors; Angiotensin II receptor blockers; Arterial hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; VALSARTAN; VASODILATOR AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHILD; CHILD CARE; CHRONIC KIDNEY FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EARLY DIAGNOSIS; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 34249699544     PISSN: 00309346     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Deutsche Liga zur Bekämpfung des hohen Blutdrucks e.V. Deutsche Hypertonie Gesellschaft. Leitlinien (www.paritaet.org/hochdruck/).
2. Sinaiko AR, et al. Hypertension in children. N Engl J Med 1996; 335: 1968-1973.
3. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996). Update on the 1987 Task Force on High Blood Pressure in Children and Adolescents. Pediatrics 1996; 98: 649-658.
4. Reichert H, et al. Ambulatory blood pressure monitoring in healthy schoolchildren. Pediatr Nephrol 1995; 9: 282-286.
5. Kirchhoff-Moradpour AH, Rump LC, Zimmerhackl LB. Arterielle Hypertonie im Kindes- und Jugendalter. pädiat prax 2002; 61: 405-417.
6. Schomig M, et al. Controversy on optimal blood pressure haemodialysis: normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 2001; 16: 469-474.
7. Killeen J, Vanderburg D, Harlan WR. Application of weight-height ratios and body indices to juveline populations; the National Health Examination Survey Data. J Chronic Dis 1978; 31; 529-537.
8. Schneeweiss A. Cardiovascular Drugs in children. II: Angiotensin converting enzyme inhibitors in pediatrics. Pediatr Cardiol 1990; 20 (Suppl C): 199-207.
9. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
10. Yusuf S, et al. Effects on an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risks patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
11. Van Rijnsoever EW, Kwee-Zuiderwijk WJ, Fennstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158: 2063-2065.
12. Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
13. Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
14. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-158.
15. Doyle AE. Role of angiotensin-converting enzyme inhibitors in preventing or reducing end-organ damage in hypertension. J Cadrdiovasc Pharmacol 1992; 19 (Suppl 5): 21-27.
16. Wühl E, Mehls O, Schaefer F, and the ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004; 66: 768-776.
17. Herrera P, et al. Effects of the ACE inhibitor lisinopril in children age 6-16 years. Am J Hypertens 2002; 15: 46A.
18. Wells T, et al. A double-blind, placebo controlled, dose-response study of the effectivness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002; 42: 870-880.
19. Bouissou F, et al. Long term therapy by captopril in children with renal hypertension. Clin Exp Hypertens 1986; 8: 841-845.
20. Chan MK, et al. Captopril in hypertension after renal transplantation. Postgrad Med J 1984; 60: 132-134.
21. Burnier M, Brunner HR. Angiotensin II Receptor antagonists. Lancet 2000; 355: 637-645.
22. Stoll M, et al. The angiotensin AT2-receptor mediated inhibition of cell proliferation in coronary endothelial cells. J Clin invest 1995; 95: 651-657.
23. Fernandez-Andrade C, et al. Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 1998; 68: 120-124.
24. Barnett AH, et al. Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Eng J Med 2004; 351: 1952-1961.
25. Waeber B. A review of irbesartan in antihypertensive therapy: comparison with other antihypertensive agents. Curr Ther Res 2001; 62: 505-523.
26. Bakris GL, et al. ACF inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000; 58: 2084-2092.
27. Reinehr T, Wabitsch M, Hrsg. Adipositas in praxi. Multimodale Konzepte für das Kindes- und Jugendalter. München: Marseille; 2007.